Macrophages emerge as the bone-forming engine in radiographic axial spondyloarthritis
Radiographic axial spondyloarthritis has long posed a frustrating biological contradiction: inflammation can soften with treatment while spinal fusion continues to advance. This study tackles that disconnect at the level of cell signaling and identifies macrophages as the central cellular drivers of pathological osteogenesis. In a tmTNF-overexpressing transgenic mouse model that spontaneously recapitulated spinal ankylosis, the disease process was not treated as a passive consequence of chronic inflammation. It was mapped as an active, inducible program of bone formation.
The work centers on transmembrane TNF reverse signaling, a mechanism that shifts attention away from TNF as a soluble inflammatory mediator and toward the membrane-bound form as a signaling platform. Single-cell RNA sequencing, genetic knockout strategies targeting TNFR1 and TNFR2, and macrophage depletion experiments converged on the same conclusion: macrophages sit upstream of the osteogenic cascade. Their activity was linked to upregulation of TGF-β3 and BMP2, two growth factors with established bone-inducing potential. In practical terms, this places macrophages in the position of instructing nearby mesenchymal stem cells to become ossifying cells rather than merely responding to inflammation after the fact.
sTNFR1 binding to tmTNF creates a reverse signaling circuit
The mechanistic centerpiece is a newly defined axis involving soluble TNFR1, tmTNF, PSMA1, and NF-κB. Soluble TNFR1 bound to tmTNF and promoted interaction between the intracellular domain of tmTNF and the proteasome subunit alpha type-1, PSMA1. From there, the pathway fed into IKKβ/NF-κB activation, which in turn increased TGF-β3 and BMP2 expression. The biology is unusually direct: a receptor-ligand interaction on macrophage surfaces was converted into a transcriptional program that favors bone formation.
This matters because the study separates inflammatory signaling from structural damage signaling. TNF blockade has already transformed symptom control in axial spondyloarthritis, yet the persistence of syndesmophyte formation has suggested that one inflammatory axis is not the whole story. Here, reverse signaling through tmTNF provides a plausible explanation for why inflammation and ossification can travel together without being biologically identical. A macrophage can be activated in a way that does not merely amplify cytokine release, but instead retools the local tissue environment toward new bone.
The model also offers a useful reminder that osteogenesis in spondyloarthritis is not a generic repair response. It is a misdirected developmental program, likely shaped by inflammatory cues that recruit bone morphogenetic pathways normally reserved for healing and tissue remodeling. By placing macrophages at the center of that switch, the study provides a cellular target rather than a vague disease abstraction.
Ikbkb silencing stopped new bone formation in the mouse model
The most clinically relevant experiment came from targeted intervention. A mannose-modified nanoparticle system was used to deliver Ikbkb siRNA to macrophages, and silencing of Ikbkb significantly inhibited new bone formation. IKKβ sits upstream of NF-κB activation, so the result fits neatly with the signaling map established earlier in the study. Blocking that node interrupted the osteogenic output rather than simply dampening the inflammatory background noise.
This is a notable distinction for a disease defined by structural progression. If a therapy can suppress inflammation without touching the downstream ossification machinery, spinal fusion may still advance. By contrast, this experiment suggests that macrophage-directed interruption of the tmTNF-PSMA1-IKKβ axis can stop the signal before it reaches the bone-forming program. The therapeutic implication is concrete: the path to disease modification in r-axSpA may run through cells and pathways that are more specific than broad cytokine suppression.
Structural damage in axial spondyloarthritis may require a different therapeutic target
The findings sharpen a question that clinicians and researchers have faced for years: why does inflammation not fully explain structural damage in radiographic axial spondyloarthritis? This study answers with a molecular bridge. Macrophages, acting through tmTNF reverse signaling, can translate inflammatory cues into osteogenic instruction. The downstream rise in TGF-β3 and BMP2 gives that bridge real tissue consequence, since both factors can promote mesenchymal stem cell ossification.
The use of a transgenic mouse model that spontaneously developed spinal ankylosis strengthens the biologic coherence of the work, but it does not erase the distance between mouse anatomy and human disease. The experiments establish mechanism, not proof of patient-level benefit. Even so, the pathway is specific enough to be actionable. Targeting tmTNF reverse signaling or the IKKβ/NF-κB arm in macrophages could, in principle, suppress structural damage while leaving broader immune functions less disrupted than with less selective approaches.
For rheumatology, the significance is less about another inflammatory mediator and more about a new map of tissue instruction. Macrophages are not just custodians of inflammation in this model; they are the architects of abnormal bone. The study positions tmTNF reverse signaling as a mechanistic link between immune activation and ankylosis, and it offers a rational therapeutic strategy aimed at the process that actually builds the bone.
What this mechanism can and cannot claim yet
The data are compelling at the level of causality inside the model system. Single-cell profiling identified the relevant cell population, genetic manipulation clarified the receptor dependence, and macrophage depletion confirmed the cellular source of the osteogenic signal. The nanoparticle experiment then showed that pathway inhibition can blunt the structural outcome. Few preclinical studies assemble mechanism and intervention this cleanly.
Still, the findings remain preclinical, and the article does not provide human efficacy, dosing, or safety data for an equivalent strategy. The therapeutic concept will need translation into human tissue studies and eventual clinical testing before it can influence routine care. What the work does provide is a mechanistic rationale for why structural progression in radiographic axial spondyloarthritis may persist despite control of inflammatory symptoms, and why a macrophage-centered approach may be needed to arrest that damage.